mibefradil
Sign in to saveMibefradil (trade name Posicor) was a pharmaceutical drug used for the treatment of hypertension and chronic angina pectoris. It is a nonselective calcium channel blocker. It was voluntary pulled from the market ten months after FDA approval, citing potential serious health hazards shown in post release studies.
Chemical data
- Formula
- C29H38FN3O3
- Molecular weight
- 495.6 g/mol
- IUPAC name
- [(1S,2S)-2-[2-[3-(1H-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl] 2-methoxyacetate
via PubChem
Research
935 papers- Mibefradil (posicor).Comprehensive therapy · 1997
- Clinical pharmacokinetics of mibefradil.Clinical pharmacokinetics · 1998
- Mibefradil: a selective T-type calcium antagonist.The American journal of cardiology · 1997
- Mibefradil: a new class of calcium-channel antagonists.The Annals of pharmacotherapy · 1998
- Mibefradil, a pharmacologically distinct calcium antagonist.Pharmacotherapy · 1998
via PubMed
Article
2 sectionsContents
- Synthesis
- References
Mibefradil (trade name Posicor) was a pharmaceutical drug used for the treatment of hypertension and chronic angina pectoris. It is a nonselective calcium channel blocker. It was voluntary pulled from the market ten months after FDA approval, citing potential serious health hazards shown in post release studies.
The mechanism of action of mibefradil is characterized by the selective blockade of transient, low-voltage-activated (T-type) calcium channels over long-lasting, high-voltage-activated (L-type) calcium channels, which is probably responsible for many of its unique properties.